Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Angiogenesis Research

Overview: Principle and Setup of Anlotinib Hydrochloride in Cancer Research

Anlotinib hydrochloride (CAS 1058157-76-8) is a next-generation multi-target tyrosine kinase inhibitor (TKI) that has rapidly become a benchmark tool in anti-angiogenic research and cancer biology. Designed to potently and selectively block the activity of critical angiogenic receptors such as VEGFR2, PDGFRβ, and FGFR1, this compound offers researchers a powerful means of dissecting the molecular underpinnings of tumor angiogenesis and growth.

Mechanistically, anlotinib acts by inhibiting phosphorylation of its target receptors, thereby disrupting the ERK signaling pathway—a central axis in endothelial cell proliferation, migration, and neovascularization. This selectivity is evidenced by nanomolar IC₅₀ values: 5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), and 11.7 ± 4.1 nM (FGFR1), outperforming established agents like sunitinib and sorafenib. Importantly, anlotinib demonstrates minimal cytotoxicity up to 1 μM, ensuring functional rather than toxic effects in cellular assays (Lin et al., 2018).

Supplied by APExBIO, Anlotinib hydrochloride is available as a stable hydrochloride salt for reliable, reproducible experimental results. Its robust pharmacokinetic profile—marked by high oral bioavailability, extensive tissue distribution (including CNS penetration), and low toxicity—makes it especially valuable for both in vitro and in vivo applications.

Stepwise Experimental Workflows: Protocols Enhanced by Anlotinib Hydrochloride

1. Endothelial Cell Migration Inhibition (Wound Healing and Transwell Assays)

The ability of anlotinib to inhibit endothelial cell migration is a critical readout for anti-angiogenic studies. Researchers typically employ wound healing (scratch) assays and Boyden chamber (transwell) migration assays using human endothelial cell lines such as EA.hy 926 or HUVECs.

1. Plate endothelial cells and allow them to reach confluence.
2. Induce migration with pro-angiogenic factors (e.g., VEGF, PDGF-BB, FGF-2).
3. Treat with graded concentrations of anlotinib (e.g., 0.1–100 nM). Ensure DMSO content remains ≤0.1%.
4. Monitor migration over 12–24 hours, imaging at defined intervals.
5. Quantify migration area or cell counts using imaging software.

Anlotinib delivers a dose-dependent inhibition of VEGF/PDGF-BB/FGF-2-driven migration, with significant reductions at nanomolar concentrations, outperforming sunitinib, sorafenib, and nintedanib in direct comparisons (Lin et al., 2018).

2. Capillary Tube Formation Assay

The capillary tube formation assay is a gold-standard in vitro model for angiogenesis. Here, endothelial cells are seeded onto Matrigel or a similar ECM substrate, promoting the formation of capillary-like structures.

1. Seed endothelial cells onto Matrigel-coated wells.
2. Add angiogenic stimuli and various concentrations of anlotinib.
3. Incubate for 6–18 hours at 37°C.
4. Image tube networks and quantify total tube length, branching points, or network area.

Data consistently show that anlotinib blocks tube formation in a concentration-dependent manner, with significant effects at low nanomolar doses. Notably, the compound suppresses both initiation and extension of tube networks, reflecting its robust anti-angiogenic activity (Lin et al., 2018).

3. In Vivo Angiogenesis Models

For translational relevance, anlotinib's efficacy is validated in models such as the rat aortic ring assay and the chick chorioallantoic membrane (CAM) assay. Researchers observe inhibition of microvessel sprouting and density, correlating with in vitro findings and highlighting utility for preclinical cancer models.

4. Molecular Pathway Analysis

Mechanistic studies leverage Western blot or phospho-ELISA to confirm inhibition of VEGFR2, PDGFRβ, and FGFR1 phosphorylation, and subsequent blockade of the ERK signaling pathway. This confirms that observed phenotypic effects directly result from tyrosine kinase signaling pathway inhibition.

Advanced Applications and Comparative Advantages

Superior Potency and Selectivity

Anlotinib exhibits superior inhibition of VEGFR2, PDGFRβ, and FGFR1 compared to first-generation TKIs. For example, its IC₅₀ values for VEGFR2 (5.6 nM), PDGFRβ (8.7 nM), and FGFR1 (11.7 nM) surpass those of sunitinib and sorafenib, supporting its selection for mechanistic and therapeutic research (Lin et al., 2018).

For a detailed mechanistic comparison, see this article, which elaborates on the atomic-level interactions and the pharmacodynamic rationale for anlotinib's benchmark status. In contrast, this resource provides a broader context, highlighting anlotinib's role in tumor microenvironment modulation and its capacity to disrupt angiogenesis more robustly than legacy inhibitors.

Low Cytotoxicity Enables Functional Assays

Anlotinib does not induce significant cytotoxicity at concentrations up to 1 μM, allowing researchers to distinguish between anti-proliferative and cytotoxic effects. This is crucial for functional assays in cancer research and supports its use in combination studies or sequential pathway analyses (related article).

Pharmacokinetics and Translational Research

In animal models, anlotinib demonstrates oral bioavailability of 28–58% in rats and 41–77% in dogs, with high plasma protein binding (93–97%) and broad tissue distribution, including CNS penetration. Its terminal half-life varies from 5.1 ± 1.6 h in rats to 22.8 ± 11.0 h in dogs, supporting diverse dosing regimens in preclinical studies. Metabolism is primarily via cytochrome P450 enzymes (notably CYP3A), and its safety profile shows a high LD₅₀ (1735.9 mg/kg), low systemic toxicity, and no significant organ or genetic toxicity. The low risk for drug-drug interactions further distinguishes anlotinib as an optimal anti-cancer compound for both mono- and combination therapy research workflows.

Hepatocellular Carcinoma and Beyond

Given the centrality of angiogenesis in hepatocellular carcinoma, glioblastoma, and solid tumor progression, anlotinib's capacity for tumor growth inhibition and tumor angiogenesis inhibition makes it a valuable tool in disease modeling, drug screening, and translational oncology research.

Troubleshooting and Optimization Tips for Anlotinib-Based Assays

• Solubility and Storage: Dissolve anlotinib hydrochloride in DMSO for stock solutions. Store at -20°C, protected from light. Avoid repeated freeze-thaw cycles to maintain potency.
• Dose Selection: Start with a nanomolar range (1–100 nM) in migration and tube formation assays. Titrate based on cell type sensitivity and endpoint readouts.
• Vehicle Controls: Always include DMSO-only controls, keeping solvent concentration ≤0.1% to avoid confounding effects.
• Assay Timing: For migration and tube formation, 6–24 hour exposure windows capture early anti-angiogenic effects without inducing off-target stress responses.
• Phosphorylation Readouts: For pathway analysis, harvest cells at 15–60 minutes post-treatment to capture acute inhibition of tyrosine kinase and ERK signaling pathways.
• In Vivo Model Optimization: For rat or mouse studies, consider oral dosing schedules aligned with the compound's half-life and tissue distribution. Monitor animal health and perform serial plasma/tissue sampling to confirm target engagement.
• Drug-Drug Interaction Studies: While anlotinib has low interaction risk, co-administration with strong CYP3A modulators should be evaluated in vitro before in vivo translation.

Future Outlook: Anlotinib Hydrochloride in Evolving Cancer Biology

Anlotinib's unique multi-target profile positions it at the forefront of anti-angiogenic research, not only for dissecting tyrosine kinase signaling pathways but also for the rational design of combination therapies. Ongoing advances in preclinical pharmacokinetics, patient-derived xenograft models, and pathway-resolved biomarker discovery are likely to expand its utility in personalized oncology and drug development pipelines.

For researchers seeking reproducibility, potency, and translational relevance, Anlotinib hydrochloride from APExBIO offers a trusted solution with a validated safety profile and robust experimental track record. Its comprehensive inhibition of VEGFR, PDGFR, and FGFR signaling—along with favorable pharmacokinetics and minimal off-target toxicity—ensures its ongoing role as a gold-standard anti-angiogenic agent for next-generation cancer biology.

To further explore mechanistic insights and complementary applications, refer to:

• Unraveling Multi-Target Angiogenesis with Anlotinib (expands on signaling and translational applications).
• Optimal Experimental Workflows for Translational Research (details stepwise protocols and comparative advantages).

As new indications and combination strategies emerge, the flexibility and performance of anlotinib hydrochloride will continue to drive innovation in anti-angiogenic and cancer research worldwide.